Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

983 related articles for article (PubMed ID: 17488686)

  • 1. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
    Robinson SP; Goldstone AH; Mackinnon S; Carella A; Russell N; de Elvira CR; Taghipour G; Schmitz N;
    Blood; 2002 Dec; 100(13):4310-6. PubMed ID: 12393626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
    Warlick ED; Tomblyn M; Cao Q; Defor T; Blazar BR; Macmillan M; Verneris M; Wagner J; Dusenbery K; Aurora M; Bachanova V; Brunstein C; Burns L; Cooley S; Kaufman D; Majhail NS; McClune B; McGlave P; Miller J; Oran B; Slungaard A; Vercellotti G; Weisdorf DJ
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1025-32. PubMed ID: 21047561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
    Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
    Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
    Bouabdallah K; Furst S; Asselineau J; Chevalier P; Tournilhac O; Ceballos P; Vigouroux S; Tabrizi R; Doussau A; Bouabdallah R; Mohty M; Le Gouill S; Blaise D; Milpied N
    Ann Oncol; 2015 Jan; 26(1):193-198. PubMed ID: 25361987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.
    Blaise D; Vey N; Faucher C; Mohty M
    Haematologica; 2007 Apr; 92(4):533-41. PubMed ID: 17488664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
    Mohty M; Boiron JM; Damaj G; Michallet AS; Bay JO; Faucher C; Perreau V; Bilger K; Coso D; Stoppa AM; Tabrizi R; Gastaut JA; Michallet M; Maraninchi D; Blaise D
    Bone Marrow Transplant; 2004 Jul; 34(1):77-84. PubMed ID: 15133485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.